ArticleMolecular therapy oncolytics2016

Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model.

Matheus Hw Crommentuijn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.